T-lymphocyte subsets – procedural depletion (TCD)

T-lymphocyte subsets – procedural depletion refers to the ex vivo mechanical or physical removal of T-cells from a hematopoietic stem cell graft to prevent graft-versus-host disease (GVHD) (Source: PubMed, PMID: 23547547). This process is distinct from pharmacological depletion as it does not rely on the systemic administration of drugs that bind to molecular targets in vivo. Common techniques include CD34+ positive selection or CD3/CD19 negative selection using immunomagnetic bead systems like CliniMACS (Source: NIH, ClinicalTrials.gov). By removing donor T-cells, the procedure significantly reduces the incidence of acute and chronic GVHD, which is a major cause of morbidity in allogeneic transplants. However, the non-selective removal of T-cells can lead to delayed immune reconstitution and a higher risk of viral infections such as CMV or EBV (Source: StatPearls, NBK560714). It also risks diminishing the graft-versus-leukemia (GVL) effect, potentially increasing the rate of cancer relapse in patients with hematologic malignancies. Modern procedural variations aim for selective depletion of specific subsets, such as TCR alpha/beta+ T-cells, to maintain protective immunity while preventing GVHD. This approach is considered a cellular engineering process rather than a traditional drug-target interaction.

Other names

T-cell depletionT-lymphocyte depletionEx vivo T-cell depletionGraft T-cell depletionSelective T-cell depletion

Ex vivo physical or mechanical removal of T-lymphocytes from a cellular product (e.g., peripheral blood stem cells or bone marrow) using immunomagnetic separation or density gradient centrifugation to prevent alloreactive immune responses.